Feed ME
ME

23andMe Holding Co.

ME · NASDAQ

$0.61 N/A (+$0.61)
Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Weak
3/9
Valuation
-
N/A
P/FCF N/A
P/E N/A
EV/FFO N/A
Growth
-
N/A
FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A
Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
-
N/A
ROA N/A
ROIC N/A
Asset turnover N/A
Debt
-
N/A
Debt/Assets N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Stability
63 /100
Moderate
Beta 1.20x
Profitable years N/A
Rev. volatility N/A

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ME
Online

About the company

23andMe Holding Co. is an American biotechnology company specializing in genetic testing and DNA analysis for personal genetic information and health insights. Their services enable individuals to obtain information about their genetic ancestry, predisposition to certain diseases, and health-related risk factors. The company also conducts research in the field of genetics and collaborates with pharmaceutical companies on the development of new drugs and therapies based on genetic data. Their platform is known for its high standard of privacy protection and transparency in the use of genetic data. 23andMe Holding Co. shares could be an interesting choice for investors looking for opportunities in genetic research and biotechnology.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Joseph Selsavage

Employees

560

Headquarters

South San Francisco

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.